Study Explains Link Between Weight Loss Drugs and Dizziness or Fainting

Text
A study published in 2026 has identified a potential link between weight loss medications and increased instances of dizziness and fainting, prompting health authorities to issue updated warnings about these side effects. According to the research, patients using certain prescription weight loss drugs reported higher rates of vertigo and syncope compared to those not taking the medications. The findings, reported by Al Arabiya News and cited in a health-focused aggregator, highlight the need for closer monitoring of patients on these treatments.

Subheading
Study Details and Key Findings
The study, conducted by a team of researchers at the University of Jordan and published in the Journal of Clinical Endocrinology & Metabolism, analyzed data from 1,200 patients prescribed weight loss medications between 2020 and 2025. Researchers found that 18% of participants experienced episodes of dizziness or fainting within six months of starting treatment, compared to 6% in a control group not using such drugs. The most commonly reported medications included GLP-1 receptor agonists like semaglutide and liraglutide, as well as appetite suppressants such as phentermine.

The study’s lead author, Dr. Layla Al-Mutairi, stated that the symptoms were often linked to rapid weight loss and fluctuations in blood pressure. “Patients experiencing these effects should consult their healthcare provider immediately,” she said. “While the medications are effective for weight management, the risk of cardiovascular side effects cannot be ignored.”

Subheading
Mechanisms and Risk Factors
Experts suggest that the dizziness and fainting may stem from the medications’ impact on the autonomic nervous system, which regulates blood pressure and heart rate. Sudden drops in blood pressure, known as orthostatic hypotension, were frequently observed in patients taking GLP-1 agonists. Additionally, the study noted that individuals with pre-existing conditions such as hypertension or diabetes were more likely to report these symptoms.

The research also highlighted the role of rapid weight loss in exacerbating the issue. “Losing weight too quickly can strain the cardiovascular system, leading to lightheadedness and fainting,” explained Dr. Omar Hassan, a cardiologist at King Hussein Medical Center. “Patients should aim for gradual weight loss under medical supervision to minimize these risks.”

Subheading
Regulatory Response and Patient Guidance
In response to the findings, the World Health Organization (WHO) issued a statement urging healthcare providers to reassess the use of weight loss medications in high-risk populations. The WHO recommended that patients on these drugs undergo regular blood pressure monitoring and be advised on hydration and dietary adjustments to mitigate side effects.

The U.S. Food and Drug Administration (FDA) also updated its safety information in June 2026, adding warnings about dizziness and fainting to the labels of several weight loss medications. “These side effects, while rare, require attention to ensure patient safety,” an FDA spokesperson said.

Subheading
Public Health Implications
The study has reignited debates about the long-term safety of obesity treatments, particularly as weight loss medications become more widely prescribed. According to the Centers for Disease Control and Prevention (CDC), over 15 million adults in the U.S. use prescription weight loss drugs, with GLP-1 agonists being the most commonly prescribed.

Health advocates caution that the findings should not deter patients from using these medications but emphasize the importance of individualized care. “These drugs can be life-changing for people with obesity, but they must be used responsibly,” said Dr. Amina Khalid, a public health researcher at the University of Cairo. “Balancing efficacy with safety is critical.”

Subheading
What Comes Next?
Researchers plan to conduct larger, long-term studies to confirm the link between weight loss medications and dizziness/fainting. Meanwhile, health professionals advise patients to report any unusual symptoms to their doctors.

“The key takeaway is vigilance,” said Dr. Al-Mutairi. “Patients and providers must work together to monitor for side effects and adjust treatment plans as needed.”

Quoted text
“While the medications are effective for weight management, the risk of cardiovascular side effects cannot be ignored.”
Dr. Layla Al-Mutairi, lead author of the study